An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
View/ Open
Date
2017-10Author
Kasper, B
Baumgarten, C
Garcia, J
Bonvalot, S
Haas, R
Haller, F
Hohenberger, P
Penel, N
Messiou, C
van der Graaf, WT
Gronchi, A
Desmoid Working Group
Type
Journal Article
Metadata
Show full item recordAbstract
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
Collections
Subject
Desmoid Working Group
Humans
Fibromatosis, Aggressive
Randomized Controlled Trials as Topic
Research team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials
Language
eng
Date accepted
2017-06-13
License start date
2017-10
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (10), pp. 2399 - 2408